Senté has renewed its Chief Scientific Advisor agreement with Harvard Medical School and former AAD president, Richard Gallo M.D.
The agreement extends the longstanding partnership between Dr. Gallo and Senté that has helped shape the company's scientific foundation and clinical direction since its inception.
Related: Medical-Grade Skincare Brand Senté Secures Growth Funding, New CEO
As a globally recognized leader in dermatology and skin biology, Dr. Gallo has served as a key scientific advisor to Senté from the beginning, playing a central role in the research and development of the company's patented Heparan Sulfate Analog (HSA) technology. He also led the pivotal studies supporting the clinical efficacy of Senté's proprietary HSA molecule, helping establish the scientific credibility behind the brand's clinically proven formulations.
Under the renewed agreement, Dr. Gallo will continue to advise Senté on its clinical research initiatives, product innovation pipeline, and broader scientific strategy as the company advances next-generation skincare solutions grounded in regenerative skin science.
"Dr. Gallo's contributions to Senté have been foundational to who we are as a science-driven skincare company," said Zubin Meshginpoosh, President and CEO of Senté. "His expertise, leadership, and pioneering work around skin immunity and repair have helped validate our patented HSA technology and continue to guide our innovation efforts as we expand our clinical and development programs."
